Artiva Biotherapeutics (ARTV) Stock Price, News & Analysis

Company Overview

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors. By combining gene-editing technologies with optimized cell expansion processes, the company aims to enhance tumor targeting, persistence and safety profiles. Its platform supports rapid manufacturing and scalable production, potentially enabling broader patient access and faster clinical development timelines.

Founded in 2016 and headquartered in Cambridge, Massachusetts, Artiva Biotherapeutics operates in key biopharma hubs across North America and Europe. The company’s management team brings collective expertise in immuno-oncology, cell therapy manufacturing and clinical development, positioning Artiva to advance its candidate programs through pivotal trials and, ultimately, regulatory approval.

Key Stats

• Today's Range: $11.21 to $11.85
• 50-Day Range: $8.00 to $11.78
• 52-Week Range: $2.22 to $14.53
• Volume: 457,491 shs
• Average Volume: 346,317 shs
• Market Capitalization: $572.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $39.00
• Consensus Rating: Moderate Buy

Artiva Biotherapeutics Stock Analysis - MarketRank™

Artiva Biotherapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 606th out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Artiva Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Artiva Biotherapeutics has a consensus price target of $39.00, representing about 233.3% upside from its current price of $11.70.

Amount of Analyst Coverage

Artiva Biotherapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Artiva Biotherapeutics are expected to decrease in the coming year, from ($2.62) to ($2.79) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Artiva Biotherapeutics is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Artiva Biotherapeutics is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Artiva Biotherapeutics has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.92% of the float of Artiva Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Artiva Biotherapeutics has a short interest ratio ("days to cover") of 5.13.

Change versus previous month

Short interest in Artiva Biotherapeutics has recently increased by 11.47%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Artiva Biotherapeutics does not currently pay a dividend.

Dividend Growth

Artiva Biotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for Artiva Biotherapeutics this week, compared to 4 articles on an average week.

Search Interest

10 people have searched for ARTV on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.9 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $15,704,997.00 in company stock, which represents 2.7456% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Artiva Biotherapeutics insiders have bought 3,251.30% more of their company's stock than they have sold. Specifically, they have bought $16,188,035.00 in company stock and sold $483,038.00 in company stock.

Percentage Held by Insiders

1.80% of the stock of Artiva Biotherapeutics is held by insiders.

Percentage Held by Institutions

Artiva Biotherapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 8/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ARTV
• Previous Symbol: NASDAQ:ARTV
• CIK: 1817241
• Web: www.artivabio.com
• Phone: (858) 267-4467
• Fax: N/A
• Employees: 81
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Artiva Biotherapeutics: $39.00
• High Price Target: $41.00
• Low Price Target: $35.00
• Potential Upside/Downside: +233.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$83.86 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -53.86%
• Return on Assets: -48.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 24.16
• Quick Ratio: 24.16

Sales & Book Value

• Annual Sales: $250 thousand
• Price / Sales: 2,288.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.11 per share
• Price / Book: 1.65

Miscellaneous

• Outstanding Shares: 48,890,000
• Free Float: 48,010,000
• Market Cap: $572.01 million
• Optionable: N/A
• Beta: 2.16